ARCT vs MRVI
ARCT: Arcturus Therapeutics develops self-amplifying mRNA therapeutics and vaccines, with the first approved sa-mRNA COVID vaccine (KOSTAIVE) generating revenue while advancing pipeline programs for rare genetic diseases. MRVI: Maravai LifeSciences produces critical reagents and manufacturing services for mRNA vaccines and therapies, with CleanCap and TriLink products serving large biotech and pharmaceutical customers.
Side-by-side fundamentals
| Metric | ARCT | MRVI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.93 | $7.10 | |
| Market cap as of 2026-07-23 | $168M | $1.8B | |
| PEG as of 2026-07-23 | -0.18 | n/a | |
| Net margin as of 2026-07-23 | -143.8% | -51.1% | MRVI higher |
| Gross margin as of 2026-07-23 | n/a | +29.3% | |
| Operating margin as of 2026-07-23 | -161.5% | -82.2% | MRVI higher |
| ROE as of 2026-07-23 | -36.5% | -44.7% | ARCT higher |
| ROA as of 2026-07-23 | -28.4% | -13.0% | MRVI higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.28 | ARCT lower |
| Revenue growth (YoY) as of 2026-07-23 | -61.9% | -15.3% | MRVI higher |
| Revenue CAGR (3y) SEC XBRL | -26.4% | -40.5% | ARCT higher |
| Beta as of 2026-07-23 | 2.28 | 0.56 | |
| 1-year return as of 2026-07-22 close | -56.6% | +180.6% | MRVI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.